Navigation Links
Curemark Announces Four New Sites Participating in Autism Study
Date:12/2/2010

RYE, N.Y., Dec. 2, 2010 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that four additional sites across the country are now participating in Phase III clinical trials for the company's autism treatment CM-AT.  The new trial sites are:

  • Institute for Behavioral Medicine, Smyrna, Georgia
  • Cyn3rgy Research, Gresham, Oregon
  • Westside Medical Clinic, Clinton, Utah
  • Oklahoma University Physician's Child Study Center, Oklahoma City

There are now a total of 19 sites nationally conducting Phase III trials for Curemark's autism therapy.  The study is targeting a total enrollment of 170 children.

"We have been extremely pleased with the response and the level of participation in the CM-AT autism study," said Dr. Joan Fallon, Curemark founder and CEO.  "Enrollment is continuing to proceed well at our other trial sites throughout the country."

CM-AT, which has received Fast Track status from the FDA, targets enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the availability of amino acids, the building blocks of chemicals essential for brain function.  If approved, CM-AT will be one of the first therapies to address the underlying physiology of autism.  

For information on enrolling in the Curemark CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant
2. Curemark Moderates Autism Panel at Life Sciences Summit 2010
3. Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference
4. James F. Szigethy Named Curemarks Director of New Product Development
5. Curemark to Present at BioPharm America™ 2010
6. Curemark to Present at the Rodman & Renshaw Annual Global Investment Conference
7. Curemark Opens Autism Trials at New Jersey Site
8. Curemark Begins Autism Trials at Two More Sites
9. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
10. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
11. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... -- Researchers from DRUGSCAN ® and INC Research ® ... complimentary webinar titled, "Untangling methods to tamper with opioid ... on Wednesday June 28, 2017 from 12:00 PM to ... feature interviews with recreational and dependent prescription opioid abusers ... use to prepare opioid tablets for routes of administration ...
(Date:6/14/2017)... June 14, 2017  In 2016, Embodied Labs ... pitch competition and came away with $25,000 in ... described by Forbes as "entering the life of another" ... as teaching "empathy to medical professionals in an entirely ... recently named a finalist for the Department of Education,s ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Drs. Steven Crandall, Karen Johnson and Kathy Lopez ... and Upper St. Clair, PA, without a referral. The doctors address jaw pain ... the temporomandibular joint and facial muscles that support it. , Jaw pain can ...
(Date:6/28/2017)... IL (PRWEB) , ... June 28, 2017 , ... Eating ... shows that every 62 minutes, at least one person dies as a direct result ... a greater need exists for qualified treatment providers. The iaedp Foundation meets this challenge ...
(Date:6/28/2017)... ... , ... Park Systems , a leader in Atomic Force Microscopy (AFM) ... and Park customers on July 11, 2017 from 12-2pm at the Thirsty Bear Brewing ... of Park Systems, and Prof. Krishna Saraswat , Rickey/Nielsen Professor in the School ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... financial consultations to communities in northern Virginia and DC, is announcing a cooperative ... for patients with Alzheimer’s and other disorders that lead to memory impairment. , ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands that for many ... trust the sponsor to pay them correctly and on time. As the search for ... strategies that encourage sites to work on their studies. , At a complimentary live ...
Breaking Medicine News(10 mins):